| |
Dear Colleagues,
Winning the war against cancer has been the focal point of pharmaceutical and medical research for over 40 years. A single “cure-all” drug for cancer have not yet been developed even though many new cancer treatment strategies and drug targets have recently been discovered. The diversity of the many cancer types and the complexity of their mechanisms have contributed to a conundrum that researchers had strived to solve for many decades. The complexity requires researchers and regulators to join forces to fight cancer diseases in all frontiers.
The 7th Annual Cancer Drugs Research and Development Conference on January 28-29, 2010 - San Diego, California, USA will provide an extensive look at the successes as well as the challenges that face modern cancer drug development and provide you with an update on cancer drugs currently in development through clinical trials. A look at novel compounds and emerging targets will prime you with the future direction of cancer drugs with key topics to be discussed by leading experts including TRAIL-Receptor Agonists, anti-cancer antibodies, GDC-0449, BCL-xl Inhibitors, Antibody-Drug Conjugates, VEGF Receptor inhibitors, Wnt signal transduction pathway, NEDD8 activating enzyme, Hippo Tumor Suppressor Pathway, Hsp90 Inhibitors, Non-Invasive Small Animal Imaging, and much more. Elizabeth Stafford, Ph.D., Scientific Reviewer, FDA/CDRH/OIVD, a featured presenter, will discuss FDA`s perspective of the war against cancer.
The sessions will cover the following:
Session I: Targeting
Session II: Monoclonal Antibodies
Session III: Challenges of Modern Cancer Drugs
Session IV: Novel Approaches and Emerging Targets
Session V: Cancer Drugs in Clinical Trials
Learn, brainstorm and collaborate with your colleagues by signing up today!
We look forward to seeing you in San Diego.
Best Regards,
2010 Cancer Drugs Organizing Committee
FEATURED PARTNER PUBLICATION:
 |
Attend ONE Additional Conference of your choice for only $400 more. Click here to sign up!
|
| |
|
 |
Attend ALL 2009 GTCbio Conferences for only $3000.
Click here to sign up!
|
|
|
KEYNOTE SPEAKER:
Joseph Bolen, Ph.D.
Chief Scientific Officer
Millennium Pharmaceuticals: The Takeda Oncology Company
FEATURED SPEAKER:
Elizabeth Stafford, Ph.D, Scientific Reviewer, FDA/CDRH/OIVD
|